Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 11/20 | 0.76 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19982150 | 0.92 | YAP1 (0.62) | YAP1P2RX7CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL19982082 | 0.92 | YAP1 (0.62) | YAP1P2RX7CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL19975033 | 0.89 | YAP1 (0.62) | YAP1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL19975035 | 0.89 | YAP1 (0.62) | YAP1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL19982071 | 0.86 | YAP1 (1.00) | YAP1 | |
| SCHEMBL19982265 | 0.83 | YAP1 (0.76) | YAP1MEN1ALDH1A1KMT2A | |
| SCHEMBL22929145 | 0.82 | YAP1 (0.51) | YAP1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL19982125 | 0.80 | YAP1 (0.57) | YAP1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6161729 | 0.80 | BCL2 (0.64) | YAP1MEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL3350988 | 0.80 | BCL2 (0.64) | YAP1MEN1ALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999695-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20230234924-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234924-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234924-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11530182-B2 | YAP1 inhibitors that target the interaction of YAP1 with Oct4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530182-B2 | YAP1 inhibitors that target the interaction of YAP1 with Oct4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210130297-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-05-06 | — | — | US | disclosed |
| US-10906874-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| WO-2018053446-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906874-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | YAP1, IWS1, YES1 | YAP1 1/4885P2RX7 3529/4885CYP3A4 4647/4885 |
| US-20210130297-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | YAP1, YES1, MYC | YAP1 1/4885P2RX7 3466/4885CYP3A4 4543/4885 |
| US-11999695-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | YAP1, YES1, MYC | YAP1 1/4885P2RX7 3337/4885CYP3A4 4446/4885 |
| US-20230234924-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | YAP1, YES1, MYC | YAP1 1/4885P2RX7 3337/4885CYP3A4 4446/4885 |
| US-11530182-B2 | YAP1 inhibitors that target the interaction of YAP1 with Oct4 | YAP1, YES1, MYC | YAP1 1/4885P2RX7 3466/4885CYP3A4 4543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.